**SHORT REPORT**

The “pulvinar sign” in a case of paraneoplastic limbic encephalitis associated with non-Hodgkin’s lymphoma

M Mihara, S Sugase, K Konaka, F Sugai, T Sato, Y Yamamoto, S Hirota, K Sakai, S Sakoda

This report describes a 59 year old woman with paraneoplastic limbic encephalitis associated with diffuse large B cell lymphoma. Her brain magnetic resonance imaging scan showed bilateral posterior thalamic hyperintensities, similar to the “pulvinar sign”. Her symptoms included progressive psychiatric disturbance and resembled the initial symptoms of variant Creutzfeldt–Jakob disease (vCJD). Clinicians should consider this treatable disorder in the differential diagnosis of vCJD.

Paraneoplastic neurological syndromes (PNS) are disorders of the nervous system that are associated with cancer but are not caused by the tumor growth itself or by non-metastatic complications such as secondary infections and metabolic, ischaemic or nutritional disorders. Paraneoplastic limbic encephalitis (PLE) is a subtype of PNS, characterised by personality changes, irritability, depression, seizures, memory loss and dementia. The most frequent magnetic resonance imaging (MRI) abnormalities in PLE are hyperintensity signals on T2-weighted or fluid attenuation inversion recovery (FLAIR) images involving one or both medial temporal lobes. Thalamic involvement has rarely been described. In this paper, we report the first case of PLE associated with non-Hodgkin’s lymphoma showing bilateral hyperintensity signals in the posterior thalamus—known as the “pulvinar sign”.

**CASE REPORT**

The patient was a 59 year old woman, who worked as a medical clerk. Her medical history was unremarkable except for a hysteromyoma. In October 2003, she noticed that she had lost 10 kg over a period of two months. She consulted a medical clerk. Her medical history was unremarkable except for a hysteromyoma. In October 2003, she noticed that she had lost 10 kg over a period of two months. She consulted a medical clerk. Her medical history was unremarkable except for a hysteromyoma. In October 2003, she noticed that she had lost 10 kg over a period of two months. She consulted a medical clerk. Her medical history was unremarkable except for a hysteromyoma. In October 2003, she noticed that she had lost 10 kg over a period of two months. She consulted a medical clerk. Her medical history was unremarkable except for a hysteromyoma. In October 2003, she noticed that she had lost 10 kg over a period of two months. She consulted...

**Table 1** Neuropsychological examination results of the patient

<table>
<thead>
<tr>
<th>Test battery (normal)</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mini Mental State Examination</td>
<td>24/30</td>
</tr>
<tr>
<td>Digit span (F &gt; 5 B &gt; 3)</td>
<td>Forward: F 6; backward: B 4</td>
</tr>
<tr>
<td>Frontal Assessment Battery</td>
<td>13/1</td>
</tr>
<tr>
<td>Wechsler Adult Intelligence Scale Revised</td>
<td>VIQ 83; PIQ 89; IQ 86</td>
</tr>
<tr>
<td>Wisconsin Card Sorting Test</td>
<td>Achieved categories: CA 1</td>
</tr>
<tr>
<td>(CA: &gt;4.2 PE &lt;4.0)</td>
<td>Perseverative error: PE 11</td>
</tr>
<tr>
<td></td>
<td>Non-perseverative error 5</td>
</tr>
<tr>
<td>Verbal fluency</td>
<td>Letter 5/minute</td>
</tr>
<tr>
<td>(letter &gt;7.6 category &gt;13.6)</td>
<td>Category 5.3/minute</td>
</tr>
</tbody>
</table>

Ataxia were not evident. Routine blood and chemistry tests including C reactive protein, vitamin B12, and vitamin B12 were normal. Serum virus screening test was negative for human immunodeficiency virus, human T lymphotrophic virus I, herpes simplex and varicella zoster viruses, cytomegalovirus, Epstein–Barr virus, measles, hepatitis B and hepatitis C virus. Serum screening for syphilis was also negative. Thyroid functions were within the normal range. Antinuclear antibody was weakly positive (×40), but other autoantibodies were negative. Immune electrophoresis was also normal. Neurone specific enolase was slightly elevated in the serum (13.7 ng/ml), but other tumour markers including carcinoembryonic antigen, CA 19-9, CA 15-3, pro-gastrin releasing peptide and soluble interleukin-2 receptors were within the normal range. Cerebrospinal fluid (CSF) examination showed normal cell counts (4 lymphocytes/μl) without abnormal cells and elevated total protein (56 mg/dl) and IgG index (1.39). CSF oligoclonal bands were positive and 14-3-3 protein was negative. Serum and CSF screening for antineuronal antibodies were negative including anti-Hu, anti-Yo, anti-Ri, anti-Ta, anti-Ma, antiamphiphysin and CRMP-5. Electroencephalography revealed normal background activity with bilateral sporadic frontal spikes. Moreover, spike and wave activities, induced by photic stimulation, were also observed. Analysis of the prion protein gene revealed methionine homozygosity at codon 129 without any mutations.

Recurrent brain MRI revealed high intensity signals in the left hippocampi in addition to bilateral posterior thalamus (fig 1B, C). A computed tomography (CT) scan of the chest revealed an enlarged left axillary lymph node. In addition, gallium citrate uptake was evident in the left axillary lymph node (fig 1D), which was dissected. Pathological examination revealed diffuse large B cell lymphoma (fig 1E–G). Adjunctive chemotherapy was started.

**Abbreviations:** CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; PLE, paraneoplastic limbic encephalitis; vCJD, variant Creutzfeldt–Jakob disease

---

**References:**

1. Creutzfeldt–Jakob disease
2. Paraneoplastic neurological syndromes
3. Magnetic resonance imaging; PLE, paraneoplastic limbic encephalitis; vCJD, variant Creutzfeldt–Jakob disease
The pulvinar sign in a case of PLE

chemotherapy was planned, but the patient refused to undergo chemotherapy. During the observation period of four months, she had no sign of recurrence of lymphoma and her neurological symptoms were stable.

**DISCUSSION**

PLE is a rare disorder and is hard to diagnose. The prominent clinical features of our patient were the neuropsychological symptoms that had developed over months. There was no evidence of intracranial malignancy, cerebrovascular disease, or metabolic abnormality. Only mild inflammatory changes were observed in the CSF without any abnormal cells. The lymphoma was localised to the left axillary lymph node. Further, the neurological symptoms did not deteriorate after the resection of the left axillary lymph node. These findings and the case history of the patient fulfil the diagnostic criteria of PLE, recently proposed by Gultekin and colleagues. Neoplasms commonly associated with PLE are carcinoma of the lungs, testis, and breasts. Association of non-Hodgkin’s lymphoma with PLE is rare, and only two cases have been reported previously. Furthermore, thalamic involvement, which is rare in PLE, was not observed in these cases. Scheid et al reported a case of PLE with breast cancer involving bilateral medial temporal lobes, cingulated gyrus, and thalamus. Nakahama et al reported a case of pathologically proved PLE predominantly involving the thalamus with gastric cancer. In a series of 50 cases studied by Gultekin and colleagues, only one patient exhibited thalamic involvement.

Bilateral symmetrical hyperintensity signals in the posterior thalami are regarded as the “pulvinar sign”, which is a characteristic of variant Creutzfeldt–Jakob disease (vCJD). The pulvinar sign in vCJD is defined as “bilateral, symmetrical pulvinar high signal relative to the signal intensity of other deep grey matter nuclei and cortical grey matter”. Collie and colleagues reported that 85% of the initial MR images of patients with vCJD were positive for the pulvinar sign. They suggested that this sign became positive early in the disease course. They concluded that the sign is a sensitive and unique finding in vCJD. However, bilateral thalamic hyperintensity is not entirely specific to vCJD. Similar neuroradiological manifestations have been reported in several disorders including benign intracranial hypertension, Alpers’ syndrome, acute encephalitis, post-infection encephalitis, Wernicke’s encephalopathy and cat-scratch disease. However, clinical or other neuroradiological features have helped in distinguishing these disorders from vCJD.

Establishment of the surveillance case definition of vCJD could improve its clinical diagnostic accuracy, but early diagnosis of vCJD is still difficult because specific neurological features including sensory disturbance, cerebellar ataxia, and involuntary movement are often absent at disease onset and develop later. The present patient did not fulfil the case definition of vCJD at the time of admission, yet it was difficult to exclude the possibility of vCJD. The follow up MRI revealed hippocampal involvement, and the patient’s symptoms ceased to deteriorate after the resection of the lymph node. These neuroradiological and clinical features are unlike those observed in vCJD and helped us suspect PLE. In addition, it should be noted that a patient with PLE could develop clinical features similar to those of vCJD including psychiatric symptoms, cerebellar ataxia, or sensory disturbances; a case of limbic encephalitis has been reported from among pathologically confirmed, misdiagnosed cases of vCJD. Therefore, a systematic examination including screening for malignancies and repeated cranial MRI should be considered for detecting this treatable differential diagnosis.

In summary, we report the first case of PLE with non-Hodgkin’s lymphoma exhibiting the pulvinar sign on
T2-weighted MRI. The exclusion of other possible disorders, especially treatable disorders such as PLE, is important in the differential diagnosis of vCJD. It is noteworthy that PLE may exhibit clinical and neuroradiological manifestations similar to those of vCJD.

ACKNOWLEDGEMENTS

We thank Professor K Doh-ura (Tohoku University) and Professor T Kitamoto (Tohoku University) for detection of 14-3-3 protein and analysis of the prion protein gene of the patient.

Authors’ affiliations

M Mihara, S Sugase, K Konaka, F Sugai, T Sato, Y Yamamoto, S Sakoda, Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
S Hirota, Department of Pathology, Osaka University Hospital, Suita, Osaka, Japan
K Sakai, Department of Neurology, Kanazawa Medical University, Ishikawa, Japan

Competing interests: none declared

Correspondence to: M Mihara, Department of Neurology, Osaka University Graduate School of Medicine, D-4, 2-2, Yamadaoka, Suita, Osaka 565-0871, Japan; m-mihara@neurol.med.osaka-u.ac.jp

Received 14 July 2004
Revised version received 11 September 2004
Accepted 15 September 2004

REFERENCES


